Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2)
暂无分享,去创建一个
S. Mayer | R. Higashida | E. Keller | A. Molyneux | R. Macdonald | A. Raabe | P. Vajkoczy | R. Macdonald | I. Wanke | S. Roux | N. Kassell | D. Bach | A. Marr | A. Frey
[1] Paul Vespa,et al. Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2012, Stroke.
[2] R. Macdonald,et al. Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[3] S. Mayer,et al. Preventing Vasospasm Improves Outcome After Aneurysmal Subarachnoid Hemorrhage: Rationale and Design of CONSCIOUS-2 and CONSCIOUS-3 Trials , 2010, Neurocritical care.
[4] T. Gin,et al. Intravenous Magnesium Sulphate for Aneurysmal Subarachnoid Hemorrhage (IMASH): A Randomized, Double-Blinded, Placebo-Controlled, Multicenter Phase III Trial , 2010, Stroke.
[5] E. Wijdicks,et al. Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage , 2010, The Lancet Neurology.
[6] R. D. de Haan,et al. Effect of Statin Treatment on Vasospasm, Delayed Cerebral Ischemia, and Functional Outcome in Patients With Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis Update , 2010, Stroke.
[7] Jeffrey J. Fletcher,et al. Do Endothelin-Receptor Antagonists Prevent Delayed Neurological Deficits and Poor Outcomes After Aneurysmal Subarachnoid Hemorrhage?: A Meta-Analysis , 2009, Stroke.
[8] John H. Zhang,et al. Subarachnoid Hemorrhage: Is It Time for a New Direction? , 2009, Stroke.
[9] A. Kolias,et al. Pathogenesis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: Putative mechanisms and novel approaches , 2009, Journal of neuroscience research.
[10] E. Stroes,et al. Microthrombosis after Aneurysmal Subarachnoid Hemorrhage: An Additional Explanation for Delayed Cerebral Ischemia , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[11] S. Mayer,et al. Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1): Randomized, Double-Blind, Placebo-Controlled Phase 2 Dose-Finding Trial , 2008, Stroke.
[12] A. Dumont,et al. New insights into the causes and therapy of cerebral vasospasm following subarachnoid hemorrhage. , 2008, Drug discovery today.
[13] V. Feigin,et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. , 2007, The Cochrane database of systematic reviews.
[14] R. Macdonald,et al. Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution , 2007, Nature Clinical Practice Neurology.
[15] M. Lauritzen,et al. Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations. , 2006, Brain : a journal of neurology.
[16] B. Meyer,et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. , 2005, Journal of neurosurgery.
[17] Scott E Kasner,et al. Utility of the NIH Stroke Scale as a Predictor of Hospital Disposition , 2003, Stroke.
[18] S. Peery,et al. Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage , 2002, Neurology.
[19] K. Waterloo,et al. Prophylactic Hyperdynamic Postoperative Fluid Therapy after Aneurysmal Subarachnoid Hemorrhage: A Clinical, Prospective, Randomized, Controlled Study , 2001, Neurosurgery.
[20] C Caroselli,et al. Recommendations for the management of patients with unruptured intracranial aneurysms: A statement for healthcare professionals from the Stroke Council of the American Heart Association. , 2000, Circulation.
[21] C. Anderson,et al. Health outcomes 1 year after subarachnoid hemorrhage , 2000, Neurology.
[22] J. Marler,et al. Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators. , 1999, Stroke.
[23] Aman B Patel,et al. Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association , 1994, Stroke.
[24] H. Adams,et al. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: Overall management results. , 1990, Journal of neurosurgery.
[25] N. Kassell,et al. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. , 1985, Stroke.
[26] B. Jennett,et al. Assessment of coma and impaired consciousness. A practical scale. , 1974, Lancet.
[27] R. Macdonald,et al. Metaanalysis of Tirilazad Mesylate in Patients with Aneurysmal Subarachnoid Hemorrhage , 2009, Neurocritical care.
[28] N. Knuckey,et al. Health outcomes 1 year after subarachnoid hemorrhage , 2000 .